rasagiline has been researched along with Acute Confusional Senile Dementia in 50 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (28.00) | 29.6817 |
| 2010's | 25 (50.00) | 24.3611 |
| 2020's | 11 (22.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chorev, M; Finberg, J; Finkelstein, N; Friedman, R; Goldenberg, W; Goren, T; Gross, A; Herzig, Y; Huang, W; Krais, B; Lavian, G; Lerner, D; Miskolczi, I; Molnar, S; Rantal, F; Razin, M; Sterling, J; Tamas, T; Toth, G; Weinstock, M; Youdim, MB; Zagyva, A; Zekany, A | 1 |
| Chen, JF; Hu, MK; Lee, KP; Liao, YF; Lin, HC; Tung, YT; Wang, BJ | 1 |
| Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V | 1 |
| Huang, L; Jiang, H; Li, X; Lu, C; Luo, Z; Mao, F; Shan, W; Su, T; Sun, Y | 1 |
| Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Yang, X; Zheng, Y | 1 |
| Ai, J; Deng, Y; Li, Y; Liu, Q; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y | 2 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, X | 1 |
| Liu, W; Ma, Q; Pan, W; Sang, Z; Wang, K; Yu, L | 1 |
| Cai, P; Kong, LY; Li, F; Liu, QH; Wang, J; Wang, XB; Wu, JJ; Yang, XL | 1 |
| Han, X; Liu, W; Ma, Q; Sang, Z; Wang, H; Wang, K; Ye, M; Yu, L | 2 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Xu, R; Yang, J; Zhang, X | 1 |
| Deng, Y; Li, Y; Liu, H; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, Z; Zhang, X; Zheng, Y | 1 |
| Alcaro, S; Bagetta, D; Borges, F; Cagide, F; Oliveira, PJ; Ortuso, F; Pérez, C; Reis, J; Rodríguez-Franco, MI; Teixeira, J; Uriarte, E; Valencia, ME | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K; Zhang, P | 1 |
| Fan, X; Liu, W; Sang, Z; Shi, J; Wang, K; Yang, D; Zhang, P; Zhang, Z; Zhu, G | 1 |
| Bai, P; Cheng, X; Cheng, Y; Lu, X; Sang, Z; Shi, J; Wang, K; Yang, J; Zhang, P; Zhang, Q; Zheng, C | 1 |
| Miao, Y; Sun, J; Wang, X; Yang, J; Yun, Y | 1 |
| Cao, Z; Deng, Y; Liu, Z; Song, Q; Tan, Z; Yang, Z; Yu, G | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z | 1 |
| Bai, P; Chen, Z; Lan, Y; Liu, W; Qiao, Z; Sang, Z; Shi, J; Tan, Z; Wang, C; Wang, K; Wang, Y; Wu, A; Zhao, Y; Zhu, G | 1 |
| Cheng, M; Guo, J; Jiang, N; Li, Q; Liang, N; Liu, J; Nong, X; Pang, C; Qin, Y; Tang, C; Tang, W; Xie, SS; Zhang, Z | 1 |
| Andrys, R; Capek, J; Handl, J; Hrabinova, M; Janockova, J; Kobrlova, T; Korabecny, J; Marco-Contelles, JL; Mezeiova, E; Micankova, P; Muckova, L; Nepovimova, E; Pejchal, J; Rousar, T; Simunkova, M; Soukup, O; Valko, M | 1 |
| Cao, Z; Cong, S; Deng, Y; Liu, Z; Song, Q; Tan, Z; Yu, G | 1 |
| Cao, Z; Deng, Y; Sang, Z; Song, Q; Tan, Z; Zhang, L | 1 |
| Alcaro, S; Borges, F; Chavarria, D; Gaspar, A; Mesiti, F | 1 |
| Al Mamun, A; Alim, MA; Ashraf, GM; Kabir, MT; Khatkar, A; Mathew, B; Rahman, MH; Rahman, MM; Rauf, A; Uddin, MS | 1 |
| Chung, YA; Im, JJ; Jeong, H; Na, SH; Song, IU | 1 |
| Matos, MJ | 1 |
| Abeijon, P; Caamano, O; Garcia-Mera, X; Gonzalez-Diaz, H; Lopez-Castro, E; Romero-Duran, FJ; Yanez, M | 1 |
| Amit, T; Avramovich-Tirosh, Y; Bar-Am, O; Mandel, S; Weinreb, O; Yogev-Falach, M; Youdim, MB | 1 |
| Korczyn, AD; Vakhapova, V | 1 |
| Fridkin, M; Youdim, MB; Zheng, H | 2 |
| Campagna, F; Carotti, A; Catto, M; Leonetti, F; Nicolotti, O; Pisani, L; Stefanachi, A | 1 |
| Amit, T; Bar-Am, O; Fridkin, M; Mandel, SA; Youdim, MB; Zheng, H | 1 |
| Amit, T; Bar-Am, O; Weinstock, M; Yogev-Falach, M; Youdim, MB | 1 |
| Youdim, MB | 1 |
| Guay, DR | 1 |
| Ashani, Y; Groner, E; Herzig, Y; Schorer-Apelbaum, D; Sterling, J; Weinstock, M | 1 |
| Bejar, C; Finberg, JP; Gross, A; Poltyrev, T; Wang, RH; Weinstock, M; Youdim, MB | 1 |
| Bejar, C; Kirschbaum-Slager, N; Lazarovici, P; Shoham, S; Weinstock, M; Youdim, MB | 1 |
| Weinstock, M; Youdim, MB | 2 |
| Kupsch, A | 1 |
12 review(s) available for rasagiline and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid | 2008 |
The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Chemistry Techniques, Synthetic; Donepezil; Dopamine Agents; Drug Design; Drug Discovery; Humans; Indans; Memantine; Molecular Targeted Therapy; Neuroprotective Agents; Nootropic Agents; Rivastigmine; Tacrine | 2019 |
Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion?
Topics: Alzheimer Disease; Donepezil; Drug Synergism; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Protein Aggregates; Small Molecule Libraries | 2021 |
Multi-Target Mining of Alzheimer Disease Proteome with Hansch's QSBR-Perturbation Theory and Experimental-Theoretic Study of New Thiophene Isosters of Rasagiline.
Topics: Alzheimer Disease; Humans; Indans; Models, Theoretical; Neuroprotective Agents; Proteome; Quantitative Structure-Activity Relationship; Thiophenes | 2017 |
Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cell Cycle; Cell Survival; Drug Design; Enzyme Activation; Humans; Hydroxyquinolines; Indans; Iron Chelating Agents; MAP Kinase Signaling System; Nerve Growth Factors; Neurons; Neuroprotective Agents; Protein Kinase C | 2009 |
Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases.
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents; Antioxidants; Chelating Agents; Cholinesterase Inhibitors; Drug Design; Drug Discovery; Free Radical Scavengers; Humans; Indans; Ligands; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Nitric Oxide Synthase | 2011 |
From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Cycle Checkpoints; Chelating Agents; Cholinesterase Inhibitors; Humans; Hydroxyquinolines; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oligopeptides; Piperazines | 2012 |
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Brain; Chelating Agents; Cholinesterase Inhibitors; Cholinesterases; Culture Media, Serum-Free; Dementia; Dopamine; Dose-Response Relationship, Drug; Humans; Indans; Iron; Lewy Bodies; MAP Kinase Signaling System; Models, Chemical; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Neurons; Piperazines; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Quinolines | 2005 |
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Humans; Hydroxyquinolines; Indans; Models, Biological; Neuroprotective Agents; Parkinson Disease; Selegiline | 2006 |
Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2006 |
Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Apoptosis; Brain; Cholinesterase Inhibitors; Humans; Indans; Neurons; Neuroprotective Agents | 2001 |
Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline.
Topics: Alzheimer Disease; Animals; Antidepressive Agents; Antiparkinson Agents; Apoptosis; Cholinesterase Inhibitors; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents | 2002 |
38 other study(ies) available for rasagiline and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Carbamates; Cattle; Cholinesterase Inhibitors; Humans; Indans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Phenethylamines; Propylamines; Structure-Activity Relationship | 2002 |
New 1,2,3,4-tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Extracellular Signal-Regulated MAP Kinases; Humans; Hydrolysis; Neuroprotective Agents; Peptide Hydrolases; Tetrahydroisoquinolines | 2008 |
Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Antioxidants; Benzylidene Compounds; Cations, Divalent; Chelating Agents; Copper; Humans; Indans; Iron; Isoenzymes; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship; Zinc | 2012 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; Chelating Agents; Copper; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Swine | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Isoflavones; Mannich Bases; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Mannich Bases; Neuroprotective Agents; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rivastigmine; Structure-Activity Relationship; Swine | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Blood-Brain Barrier; Edaravone; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Structure, Tertiary | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors; Humans; Kinetics; Models, Molecular; Monoamine Oxidase Inhibitors; Thioxanthenes; Xanthones | 2017 |
Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Chelating Agents; Cholinesterase Inhibitors; Electrophorus; Humans; Kinetics; Mannich Bases; Metals; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pyridoxine; Rats; Resveratrol; Stilbenes | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quinolines; Swine | 2017 |
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Binding Sites; Blood-Brain Barrier; Chromones; Copper; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Protein Structure, Tertiary; Rats; Reactive Oxygen Species; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phthalimides; Protein Structure, Tertiary; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Permeability; Phenols; Piperazines; Protein Structure, Tertiary; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Survival; Chalcones; Chelating Agents; Copper; Drug Design; Flurbiprofen; Humans; Lipopolysaccharides; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nitric Oxide; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Permeability; Protein Aggregates; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2018 |
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug Design; Hep G2 Cells; Humans; Ligands; Molecular Docking Simulation; Molecular Targeted Therapy; Monoamine Oxidase; Monoamine Oxidase Inhibitors | 2018 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Eels; Female; Horses; Humans; Male; Maze Learning; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase Inhibitors; Drug Design; Eels; Horses; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Development; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Transport; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Chelating Agents; Cholinesterase Inhibitors; Coordination Complexes; Copper; Drug Design; Female; Humans; Male; Memory Disorders; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Protein Binding; Scopolamine; Structure-Activity Relationship | 2019 |
Synthesis and biological evaluation of 4-arylcoumarins as potential anti-Alzheimer's disease agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumarins; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Structure, Tertiary; Structure-Activity Relationship | 2020 |
Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Clioquinol; Drug Discovery; Flurbiprofen; Humans; Ligands; Membranes, Artificial; Models, Molecular; Molecular Structure; Protein Conformation; Structure-Activity Relationship | 2020 |
Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Female; Male; Membranes, Artificial; Mice; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Permeability; Protein Aggregation, Pathological; Random Allocation; Rats | 2020 |
Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Cell Line; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Mice; Mice, Inbred Strains; Microsomes, Liver; Molecular Structure; Peptide Fragments; Positron Emission Tomography Computed Tomography; Protein Aggregates; Rats; Structure-Activity Relationship; Zebrafish | 2020 |
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cell Survival; Clorgyline; Dose-Response Relationship, Drug; Drug Design; Humans; Indans; Male; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2020 |
2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Drug Design; Humans; Naphthoquinones; Structure-Activity Relationship | 2021 |
Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Benzylidene Compounds; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Copper; Dose-Response Relationship, Drug; Electrophorus; Female; Humans; Male; Mannich Bases; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2021 |
Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Antioxidants; Binding Sites; Cell Survival; Chalcone; Drug Design; Humans; Kinetics; Metals; Molecular Docking Simulation; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Protein Aggregates; Rats; Structure-Activity Relationship | 2021 |
Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer's Disease.
Topics: Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents | 2020 |
Possible neuroprotective effects of rasagiline in Alzheimer's disease: a SPECT study.
Topics: Aged; Alzheimer Disease; Brain; Female; Humans; Indans; Male; Neuroprotective Agents; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2021 |
Delayed start, rapid solution?
Topics: Alzheimer Disease; Drug Administration Schedule; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Research Design | 2010 |
Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Chelating Agents; Cholinesterase Inhibitors; Humans; Indans; Neuroprotective Agents; Oxidative Stress; Phosphorylation | 2010 |
Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Carbamates; Cell Line; Enzyme Activation; Enzyme Inhibitors; Humans; Indans; Mitogen-Activated Protein Kinases; Neuroprotective Agents; Parkinson Disease; Rats; Signal Transduction | 2003 |
The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Humans; Indans; Inhibition, Psychological; Inhibitory Concentration 50; Kinetics; Monoamine Oxidase Inhibitors; Phenylcarbamates; Rivastigmine; Selegiline | 2007 |
TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Brain Injuries; Cholinesterase Inhibitors; Indans; Male; Memory Disorders; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Scopolamine | 2000 |
Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.
Topics: Alzheimer Disease; Animals; Anti-Bacterial Agents; Brain Injuries; Cell Death; Cell Hypoxia; Cholinesterase Inhibitors; Cholinesterases; Indans; Male; Memory; Mice; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Rats; Rats, Sprague-Dawley; Reaction Time; Streptozocin | 2001 |
Rasagiline. Teva Pharmaceutical.
Topics: Administration, Oral; Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Structure-Activity Relationship | 2002 |